CytomX Therapeutics CTMX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's enterprise value?
- CytomX Therapeutics (CTMX) reported enterprise value of $990.06M in Q1 2026.
- How has CytomX Therapeutics's enterprise value changed year-over-year?
- CytomX Therapeutics's enterprise value increased by 8529.9% year-over-year, from $11.47M to $990.06M.
- What is the long-term trend for CytomX Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), CytomX Therapeutics's enterprise value has grown at a 22.3% compound annual growth rate (CAGR), from $260.39M to $713.37M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.